Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Neurology Contract Research Organization - Global Strategic Business Report: Market to Reach US$13.1 Billion by 2032

globenewswire.com

Neurology Contract Research Organization - Global Strategic Business Report: Market to Reach US$13.1 Billion by 2032 Dublin, Oct. 28, 2026 (GLOBE NEWSWIRE) -- "Neurology Contract Research Organization - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global neurology contract research organization (CRO) market was valued at US$8.2 billion in 2025 and is projected to reach US$13.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 6.8%. Market growth is being supported by rising investment in central nervous system drug development, increasingly complex clinical trial protocols, expanding neurological disease prevalence, and demand for specialized research partners with global capabilities.

Neurology CRO Market Trends and Growth Drivers

Neurology-focused CROs are becoming increasingly important to pharmaceutical and biotechnology companies developing treatments for Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, amyotrophic lateral sclerosis, neuromuscular disorders, brain tumors, and other neurological conditions. These organizations provide specialized support across preclinical research, clinical development, regulatory affairs, pharmacovigilance, data management, medical writing, and post-marketing surveillance.

The high failure rate, extended timelines, disease heterogeneity, variable progression, placebo response, and endpoint complexity associated with neurology trials are encouraging sponsors to outsource more development activities. CROs offer access to experienced investigators, patient recruitment networks, neuroimaging capabilities, biomarker expertise, biostatistics, and regulatory strategies aligned with regional and international requirements.

Technology Is Transforming Neurology Clinical Trials

Digital transformation is strengthening the operational and analytical capabilities of neurology CROs. Advanced neuroimaging, artificial intelligence, predictive analytics, wearable monitoring devices, electronic data capture, and digital cognitive assessment tools are increasingly incorporated into study protocols. These technologies support real-time data collection, centralized monitoring, patient retention, site selection, recruitment forecasting, and analysis of electronic health records, biospecimens, brain scans, and clinical outcomes.

Decentralized and hybrid clinical trial models are also expanding participant access across geographies. This is particularly important for rare neurological disorders, long-duration neurodegenerative disease studies, and adaptive trials requiring highly targeted patient populations. The emergence of digital biomarkers and mobile health technologies is expected to accelerate demand for integrated, technology-enabled CRO services.

Market Outlook and Regional Opportunities

Clinical services represent a major growth segment and are forecast to reach US$4.0 billion by 2032, advancing at a CAGR of 7.8%. Data management services are projected to grow at a CAGR of 7.4% during the analysis period. The United States neurology CRO market was valued at approximately US$2.2 billion in 2025. China is forecast to expand at a CAGR of 10.5%, reaching US$2.8 billion by 2032. Additional opportunities are emerging across Japan, Canada, Germany, the wider Asia-Pacific region, Europe, Latin America, the Middle East, and Africa.

Globalization remains a significant market driver as sponsors seek larger, more diverse patient populations and access to specialized cohorts. CROs with international infrastructure, local regulatory knowledge, standardized data systems, and therapeutic expertise are well positioned to manage multinational studies. Strategic partnerships, mergers, acquisitions, and platform expansions are further reshaping the competitive landscape.

Report Scope

The report analyzes the global neurology contract research organization market by value and provides forecasts from 2025 through 2032.

Strategic Value of the Report

Featured Companies

Companies covered include Alimentiv Inc., Axon CRO, Atlantic Research Group Inc., Charles River Laboratories, CTI Clinical Trial & Consulting, EphyX Neuroscience, Ergomed plc, Fortrea Holdings Inc., ICON plc, IQVIA Inc., Labcorp Drug Development, MD Biosciences, Medpace Holdings Inc., Neuroservices-Alliance, Neuron Experts, Parexel International Corporation, Pharmaron Beijing Co. Ltd., PPD Inc. (Thermo Fisher Scientific), QPS Neuropharmacology, Syneos Health, and WuXi AppTec.

Domain Expert Insights

The report incorporates perspectives from specialists across industry, enterprise, and academia. The report tracks early market signals emerging from expert discussions, corporate activity, conference sessions, keynotes, panel discussions, institutional publications, annual reports, regulatory developments, and validated industry sources.

These insights connect developing signals with strategic market direction, identifying the technologies, partnerships, regional shifts, and competitive developments likely to influence future growth. Company intelligence extends beyond broad market analysis to examine the organizations shaping the neurology CRO competitive environment. Where analytically relevant, market share is evaluated by major region to reflect differences in local market structure, therapeutic capabilities, regulatory conditions, and competitive dynamics.

Key Attributes:

For more information about this report visit https://www.researchandmarkets.com/r/uxnsvq

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.